Correlations Between Serum Decoy Receptor 3 and Airflow Limitation and Quality of Life in Male Patients with Stable Stage and Acute Exacerbation of COPD
- 24 March 2020
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 198 (3) , 515-523
Abstract
Purpose Serum decoy receptor 3 (DcR3) level increases in chronic inflammatory diseases. The present study aimed to examine serum DcR3 and IL-6 levels in male patients with stable chronic obstructive pulmonary disease (COPD) and acute exacerbation of the disease and correlations between these markers and airflow limitation. Methods We measured serum DcR3 and IL-6 levels in 60 COPD patients [30 stable COPD (SCOPD), and 30 acute exacerbation of COPD (AECOPD)], and 30 control subjects and assessed their correlations with airflow limitation according to the COPD stage indicated by the global initiative for chronic obstructive pulmonary disease (GOLD) criteria, peripheral O2 saturation (SpO2), and COPD assessment test (CAT) score. We also tested associations between serum DcR3 levels and COPD patients’ clinical parameters. Results Both serum DcR3 and IL-6 levels increased with increasing severity of airflow limitation in SCOPD and AECOPD groups (P < 0.01 to 0.001). These markers also increased in patients with AECOPD compared with subjects in SCOPD group in GOLD stages III–IV (P < 0.05 to 0.001). In addition, there was a significant positive correlation between serum DcR3 level and IL-6, CAT score and smoking history (per year). Conclusion The study revealed that serum DcR3 level elevated with increasing severity of airflow limitation in male COPD patients, particularly in acute exacerbation phase. This increase was associated with a reduced quality of life and increased severity of hypoxia. These results suggest that DcR3 may be associated with the underlying pathophysiology of COPD in male patients.Keywords
Funding Information
- Ardabil University of Medical Sciences
This publication has 30 references indexed in Scilit:
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019European Respiratory Journal, 2019
- Decoy Receptor 3, a Novel Inflammatory Marker, and Mortality in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2012
- Decoy Receptor 3 Attenuates Collagen-induced Arthritis by Modulating T Cell Activation and B Cell ExpansionThe Journal of Rheumatology, 2011
- Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancerBiochemical Pharmacology, 2011
- The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluidJournal of Neuroimmunology, 2009
- Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of ExacerbationsProceedings of the American Thoracic Society, 2007
- Exacerbations of chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2007
- Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Decoy Receptor 3 Increases Monocyte Adhesion to Endothelial Cells via NF-κB-Dependent Up-Regulation of Intercellular Adhesion Molecule-1, VCAM-1, and IL-8 ExpressionThe Journal of Immunology, 2005
- Modulation of macrophage differentiation and activation by decoy receptor 3Journal of Leukocyte Biology, 2003